Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy
Ghanem, S., El Sayed, I., Basuni, A., El Sabaawy, D., Ismail, A., Elhawary, R., Shebl, N., Saad, W. (2024). Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy. EKB Journal Management System, 67(11), 71-81. doi: 10.21608/ejchem.2024.273216.9395
Samar Ebrahim Ghanem; Ibrahim El Tantawy El Sayed; Ashraf A. Basuni; Dalia El Sabaawy; Abd El- Hamid A. Ismail; Rofaida Mohamed Elhawary; Nashwa Abuel-Fetuh Shebl; Warda Othman Saad. "Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy". EKB Journal Management System, 67, 11, 2024, 71-81. doi: 10.21608/ejchem.2024.273216.9395
Ghanem, S., El Sayed, I., Basuni, A., El Sabaawy, D., Ismail, A., Elhawary, R., Shebl, N., Saad, W. (2024). 'Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy', EKB Journal Management System, 67(11), pp. 71-81. doi: 10.21608/ejchem.2024.273216.9395
Ghanem, S., El Sayed, I., Basuni, A., El Sabaawy, D., Ismail, A., Elhawary, R., Shebl, N., Saad, W. Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy. EKB Journal Management System, 2024; 67(11): 71-81. doi: 10.21608/ejchem.2024.273216.9395

Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy

Egyptian Journal of Chemistry
Volume 67, Issue 11, November 2024, Pages 71-81    PDF (4.74 M)
Document Type: Original Article
DOI: 10.21608/ejchem.2024.273216.9395
Authors
Samar Ebrahim Ghanem1; Ibrahim El Tantawy El Sayed2; Ashraf A. Basuni* 1; Dalia El Sabaawy3; Abd El- Hamid A. Ismail4; Rofaida Mohamed Elhawary2; Nashwa Abuel-Fetuh Shebl5; Warda Othman Saad5
1Department of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University
2Chemistry Department, Faculty of Science, Menoufia University
3Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University
4Department of Organic Chemistry, Faculty of Science, Menoufia University
5Hepatology and Gastroenterology department, National Liver Institute, Menoufia University
Abstract
Hepatocellular carcinoma (HCC) is a complex and multifactorial disease. There is a considerable risk of developing HCC among HCV patients treated with direct acting antiviral therapies (DAAs). This study attempts to evaluate the role of tumor growth factor beta (TGF-β1) gene expression as a prognostic marker for the development of post-DAAs HCC. Methods: The study contained 220 participants distributed into four groups: de-novo HCC (Group 1, n=70), HCC after DAAs treatment (Group 2, n=50), HCV patients treated with DAAs without complications (Group 3, n=60), and a control group (Group 4, n=40). TGF-β1 gene-expression by Real Time PCR, routine investigations and clinical assessment were assessed for all participants. HCC de-novo exhibited significantly higher TGF-β1 gene expression than the other groups (P value 0.05. Overall survival analysis showed no significant association between TGF expression in either de novo or post-DAAs developed HCC. In conclusion, serum TGF-β1 emerges as a promising marker for the occurrence of post-DAAs Hepatocellular carcinoma, exhibiting high sensitivity and specificity. Regular monitoring of TGF-β1 levels in hepatitis C virus cases following DAAs treatment can serve as a potential marker for HCC development.
Keywords
Keywords: HCV infection; HCC; DAAs; TGF-β1
Supplementary Files
Statistics
Article View: 362
PDF Download: 156